Navigation Links
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Date:4/29/2009

s, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement, including Regeneron's agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or to terminate without any product success, risks associated with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2008. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.; Bayer HealthCare AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
2. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
3. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
4. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
5. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
6. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
7. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
8. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
9. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
10. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
11. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Capnia, Inc. (NASDAQ: ... diagnostics based on its proprietary Sensalyze™ Technology Platform ... financial results for the third quarter and nine ... the completion of our initial public offering (IPO), ... recently initiated CoSense® commercial launch," said Anish Bhatnagar, ...
(Date:12/19/2014)... 18, 2014 Baptist Health Lexington is the first ... receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status ... Atrial fibrillation is the most common cardiac arrhythmia and has ... can lead to stroke and possible death. More than 5 ... have atrial fibrillation and the numbers are rapidly increasing as ...
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... Nov. 5, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... providing further clarity and context surrounding the risk ... occur with KRYSTEXXA® (pegloticase) in the treatment of ... at the American College of Rheumatology (ACR) Annual ...
... Volcano Corporation (NASDAQ: VOLC ), a ... designed to enhance the treatment of coronary and peripheral ... ( AD enosine V asodilator I ndependent ... by Volcano, will be presented in a Late-Breaking Session ...
Cached Medicine Technology:Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 2Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 3Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 4Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 5Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 6Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 7Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 8Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011 2Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011 3Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011 4
(Date:12/19/2014)... 19, 2014 Surviving Mesothelioma says thousands of ... indicates that these pipes can leach asbestos into drinking water ... full story on the Surviving Mesothelioma website. , ... natural asbestos deposits, decaying water mains made of asbestos cement ... , To protect consumers from mesothelioma , water providers ...
(Date:12/19/2014)... Thompson HealthDay Reporter ... into the United States -- along with Angelina Jolie,s ... have highlighted cracks in the nation,s public health defense ... report released Thursday. Half of U.S. states are ... disease outbreaks. That was the main conclusion of the ...
(Date:12/19/2014)... LENEXA, Kan. (PRWEB) December 19, 2014 ... dedicated exclusively to healthcare providers, has been retained to ... for Johnson Memorial Hospital in Franklin, Ind. The top ... Smith has recently placed more than 900 healthcare executives ... 100-bed, county-owned, full service hospital providing care to the ...
(Date:12/19/2014)... 2014 Novellus Healthcare Communications, LLC ... & Clinics™, an independent journal that provides practical ... caring for patients inside the pharmacy and retail ... provide optimal access to quality care, Inside Patient ... the team treating and coordinating patient care in ...
(Date:12/19/2014)... 19, 2014 Pain Free Living a ... to announce a new Superior magnetic necklace ... are the strongest neodymium magnets for the fastest pain ... developed the Superior Magnetics brand for the fastest relief ... performs magnetic therapy using Superior Magnetic Jewelry at fairs ...
Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3Health News:New Superior Magnetic Necklace Relieves Migraine Headache 2
... FACS today announced that Paphos Skincare of Ft Lauderdale, FL has finished ... in the World. The Cream is manufactured in Italy and sold worldwide ... ... -- Gary Weinberger, MD, FACS today announced that Paphos Skincare of Ft ...
... psychologists, geneticists and neuroscientists has reported that a safe ... the brain has improved spatial learning and working memory ... human use of the drug, the finding supports the ... cognitive impairment, cushion the cognitive impact of normal aging, ...
... product destroys fat cells while increasing muscle mass without a major decrease ... ... The Total Health and Rejuvenation Center have successfully used their new Hgh ... dieting. Sources at the Total Heath Center have released the preliminary results ...
... in the Feb. 1 issue of the journal SLEEP ... the longitudinal link between sleep problems and depression. Results of ... converse association was not found. These findings are consistent with ... children from the development of depression. , Results of ...
... plays a role, study suggests , , FRIDAY, Jan. 30 ... may be less likely to attempt suicide than others, ... analyzed data from almost 37,000 people who took part ... relationship between spirituality, religious worship and suicidal behavior. , ...
... small arteries at the surface of the brain redirects flow ... tissue starved of nutrients and oxygen following a stroke, a ... news," said David Kleinfeld, a physics professor at the University ... animal models of stroke. , Damage from stroke can continue ...
Cached Medicine News:Health News:The Only 100% Biologically Pure Lycopene Cream in the World 2Health News:Vascular drug found to improve learning and memory in middle-aged rats 2Health News:Study finds genetic link between sleep disorders and depression in young children 2Health News:Study finds genetic link between sleep disorders and depression in young children 3Health News:Mesh-like network of arteries adjusts to restore blood flow to stroke-injured brain 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: